Reflow soldering

New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men

Retrieved on: 
Thursday, November 9, 2023
Yale School of Medicine, CAD, IV, Treatment, Coronary artery disease, Dissection, Doctor of Philosophy, IVL, Journal, St. Francis Hospital, TLF, MACE, HR, Perforation, CT, Woman, Safety, Society, USE, Hospital, Reflow soldering, EMPOWER, Cardiovascular disease, Pharmaceutical industry, Birth control, MD, Cardiology

The one-year results from Disrupt CAD III and IV trials were recently published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) .

Key Points: 
  • The one-year results from Disrupt CAD III and IV trials were recently published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) .
  • In the patient-level pooled analysis, titled “Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes,” use of IVL for lesion preparation of severely calcified lesions had similar safety and effectiveness in women and men at a one-year follow-up.
  • At one-year, major adverse cardiovascular event (MACE) rates were not different between women and men (12.3% vs 13.2%, p=0.52) and there was no difference between women and men in target lesion failure (TLF, 10.4% vs. 11.2% p=0.43).
  • The European lead is Nieves Gonzalo, MD, PhD, Consultant Interventional Cardiologist at Hospital Clinico San Carlos in Madrid, Spain.

CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023

Retrieved on: 
Friday, May 19, 2023
Science, Cardiology, Biotechnology, Research, Health, Medical Devices, Hospitals, Clinical Trials, Montefiore Medical Center, Myocardial infarction, Heart failure, Stroke, Reflow soldering, Splenic infarction, STEMI, PPCI, Multimedia, Cardiovascular disease, PCI, MVO, MRI, Professor, Magnetic resonance, Patient, AUC, MOCA, Mortality, Death, Microangiopathy, Safety, Pharmaceutical industry, Medical imaging, COFI

The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.

Key Points: 
  • The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.
  • View the full release here: https://www.businesswire.com/news/home/20230519005005/en/
    CorFlow has developed a next-generation fully-integrated CoFI system, which will be utilized in the upcoming pivotal trial prior to be commercially available.
  • It is an investigational device limited by federal law to investigational use and is not available for commercial distribution yet.
  • MOCA I shows that we can, and will, do better for these patients.”

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

Retrieved on: 
Wednesday, September 7, 2022
Cardiology, Software, Health, FDA, Medical Devices, Hospitals, Technology, Clinical Trials, Mortality, Triangle, Patient, University, Asahi Kasei, Safety, Muscle tissue, Hospital, STEMI, PCI, Carbon, Ventilation, Solution, Infarction, Ammonia, Incidence, Heart failure, Volunteering, Physician, Diagnosis, Data management, Dialysis, EMS, Health care, Principal, MVO, Multimedia, LAD, Rehabilitation hospital, MD, WakeMed, Instagram, FDA, Percutaneous coronary intervention, Twitter, Hamad Medical Corporation, Sleep apnea, Reflow soldering, Health, Life, CPR, University of New Mexico, Pharmaceutical industry, Medical device, Facebook

The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).

Key Points: 
  • The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).
  • TherOx SSO2 Therapy is currently indicated for patients who suffer LAD STEMI heart attacks with a high mortality rate treated within six hours of symptom onset.
  • SSO2 Therapy has been shown to reduce relative infarct size damage to the heart muscle by 26% over standard of care.
  • Besides demonstrating the safety and effectiveness of SSO2 Therapy, additional endpoints include incidence of microvascular obstruction (MVO), and outcomes measures such as heart failure readmissions and quality-of-life measures.

Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

Retrieved on: 
Wednesday, June 29, 2022
Health, Clinical Trials, Cardiology, Medical Devices, Reflow soldering, Patient, CEO, Research and development, Medicine, CLI, Spur, Â, Partnership, Principal, Cardiovascular disease, Medical University of Graz, Medical school, Ischemia, Safety, Physician, MD, Multimedia, Authorization, Pharmaceutical industry, EU, Research

Reflow Medical, Inc. , a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease.

Key Points: 
  • Reflow Medical, Inc. , a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease.
  • View the full release here: https://www.businesswire.com/news/home/20220628006094/en/
    The Temporary Spur Stent System is a novel device with a patented retrievable stent system.
  • On behalf of the team here at Reflow, we offer sincere thanks and gratitude for the partnership with Professor Brodmann and her team, commented Isa Rizk, CEO and Co-founder of Reflow Medical.
  • Reflow Medical, Inc. is a private company focused on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease.

Pfizer Completes Acquisition of Arena Pharmaceuticals

Retrieved on: 
Friday, March 11, 2022
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Inc., Atopic dermatitis, Industry, Safety, Cardiology, Raynaud syndrome, Twitter, Clinical trial, Risk, General manager, Research, Facebook, Inflammation, Dermatology, Bangladesh Securities and Exchange Commission, Ulcerative colitis, Gastroenterology, Acquisition, Arena Pharmaceuticals, U.S. Securities and Exchange Commission, NYSE, Heart, Science, Reflow soldering, Patient, Nasdaq, PFE, Eosinophilic esophagitis, Standard of care, YouTube, Freedom, Caregiver, Vaccine, Child development stages, Alopecia areata, Immunology, LinkedIn, Pharmaceutical industry, Security (finance), COVID-19, Pfizer, Rheumatology

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
  • Arena has previously indicated that it expected the results of the Phase 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the first quarter of 2022.
  • Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion.
  • The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned subsidiary of Pfizer.

Pfizer to Acquire Arena Pharmaceuticals

Retrieved on: 
Monday, December 13, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Child development stages, Dermatology, Ropes & Gray, Gastroenterology, Clinical trial, OASIS, Acquisition, Arnold & Porter, Risk, Guggenheim Partners, Facebook, Communication, Inc., Forward-looking statement, LinkedIn, Immune-mediated inflammatory diseases, Arnold, Growth, ARENA, THE, Eosinophilic esophagitis, Vaccine, Safety, Alopecia areata, U.S. Securities and Exchange Commission, Webcast, Centerview Partners, NYSE, Nasdaq, Science, LLP, PFE, SEC, LLC, General manager, Research, Atopic dermatitis, GPCR, BofA Securities, Raynaud syndrome, Twitter, YouTube, Failure, Hand, Immunology, Reflow soldering, Cooley LLP, Sale, Industry, Heart, News, Patient, Ulcerative colitis, Cardiology, Pharmaceutical industry, Security (finance), Online shopping, Risk management, Inflammation, COVID-19, UC, Pfizer

Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc .

Key Points: 
  • Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc .
  • (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
  • Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.
  • Under the terms of the merger agreement, Pfizer will acquire all of the outstanding shares of Arena common stock for $100 per share in cash.

Anuncia ReFlow™ Tech Honored With Fast Company 2021 World Changing Ideas Awards

Retrieved on: 
Tuesday, May 4, 2021
Ventricular system, Reflow soldering, Soldering, Cerebrospinal fluid, Shunt, CSF, Medicine

b'LOWELL, Mass., May 4, 2021 /PRNewswire/ -- Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company\'s 2021 World Changing Ideas Awards for its ReFlow medical device platform.

Key Points: 
  • b'LOWELL, Mass., May 4, 2021 /PRNewswire/ -- Anuncia Inc., an emerging leader in cerebrospinal fluid (CSF) management, received an Honorable Mention in the Health category of Fast Company\'s 2021 World Changing Ideas Awards for its ReFlow medical device platform.
  • A panel of eminent Fast Company editors and reporters selected honorees from a pool of more than 4,000 entries across categories and the globe.
  • The ReFlow System Mini and ReFlow Smart Shunt features are under development and not available for sale.
  • For more information, please visit www.anunciainc.com .\nAbout the World Changing Ideas Awards: World Changing Ideas is one of Fast Company\'s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better.

Amtech Systems to Announce Second Quarter 2021 Financial Results on Wednesday, May 5, 2021

Retrieved on: 
Monday, April 26, 2021
Other Manufacturing, Hardware, Electronic design automation, Engineering, Technology, Semiconductor, Manufacturing, Other Technology, Soldering, BTU International, Solder, Reflow soldering

ET on Wednesday, May 5, 2021.

Key Points: 
  • ET on Wednesday, May 5, 2021.
  • Chief Executive Officer, Michael Whang and Chief Financial Officer, Lisa Gibbs will provide an overview of the results, discuss current business conditions and conduct a question and answer session.\nThe call will be available, live, to interested parties by dialing 866-269-4261.
  • Amtech\xe2\x80\x99s equipment includes diffusion, solder reflow systems, and polishing equipment and related consumables for surface preparation of various materials, including silicon carbide (\xe2\x80\x9cSiC\xe2\x80\x9d), sapphire and silicon.
  • Amtech\xe2\x80\x99s products are recognized under the leading brand names BTU International, Bruce TechnologiesTM, and PR HoffmanTM.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005216/en/\n"

Heller Industries Wins Frost & Sullivan Acclaim for Dominating the Convection Reflow Soldering Market with High-efficiency MK7 Oven Series

Retrieved on: 
Monday, March 15, 2021
Soldering, Electrical engineering, Industrial processes, Reflow oven, Reflow soldering, Metals, Wave soldering, Flux, Solder

Heller Industries pioneered convection reflow soldering in the 1980s and, since then, has been the gold standard for SMT reflow ovens.

Key Points: 
  • Heller Industries pioneered convection reflow soldering in the 1980s and, since then, has been the gold standard for SMT reflow ovens.
  • Its Mark 7 (MK7) machine series accommodates customer requests for lower Delta T and extended preventative maintenance with a new, low-height package that maintains strong visibility across the production floor.
  • Heller is the only market participant that focuses on developing intelligent SMT soldering equipment, offering product advantages such as increased connectivity, automation, and minimal manual intervention.
  • In line with this demand, it delivers a range of curing and back-end semiconductor solutions, voidless/vacuum reflow soldering, and the flux-free formic reflow soldering process," noted Samantha Fisher, Best Practices Research Analyst, Frost & Sullivan.

Heller Industries Wins Frost & Sullivan Acclaim for Dominating the Convection Reflow Soldering Market with High-efficiency MK7 Oven Series

Retrieved on: 
Monday, March 15, 2021
Soldering, Electrical engineering, Industrial processes, Reflow oven, Reflow soldering, Metals, Wave soldering, Flux, Solder

Heller Industries pioneered convection reflow soldering in the 1980s and, since then, has been the gold standard for SMT reflow ovens.

Key Points: 
  • Heller Industries pioneered convection reflow soldering in the 1980s and, since then, has been the gold standard for SMT reflow ovens.
  • Its Mark 7 (MK7) machine series accommodates customer requests for lower Delta T and extended preventative maintenance with a new, low-height package that maintains strong visibility across the production floor.
  • Heller is the only market participant that focuses on developing intelligent SMT soldering equipment, offering product advantages such as increased connectivity, automation, and minimal manual intervention.
  • In line with this demand, it delivers a range of curing and back-end semiconductor solutions, voidless/vacuum reflow soldering, and the flux-free formic reflow soldering process," noted Samantha Fisher, Best Practices Research Analyst, Frost & Sullivan.